NorthWest Biotherapeutics Inc (NWBO)

[marzan]

CassieW, when immunotherapy started those days people did not understand pseudoprogression as those scans are like xerox copies that you cannot distinguish the progression between real and pseudo. DcVaxL trial allowed those patients who thought they progressed looking at those scans were allowed to switch to the other arm, and those who were already on the vaccine arm still got the vaccine continued. And those who were not on the vaccine, got the vaccine instead. This LL says caused muddying the trial meaning causing confusion that too many were coming up with the (pseudo)progression, but at the same time most of them didn't die, while the trial is still blinded. LL says 90% of the placebos switched but everyone is living longer. I think only way to resolve this issue is by Adjudication. And adjudication can be done only after unblinding, imo. So, once you adjudicate, you can still compare placebo against treatment, and endpoints including PFS that can attain statistical strength, imo. Once the news of psudeoprogression leaked around 2015 I guess, some shorts FUDed as trial failed. But LP kept this trial going to this date, and we are here at Data Lock next week. Good Luck to all of us.